Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTMJAI)

• Drug Name: C(-GRGDfL-) Drug Info
• Synonyms: CHEMBL235999

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 15409414
  TTD Drug ID: DMTMJAI

Molecule-Related Drug Atlas

Drug(s) Targeting Integrin beta-1 (ITGB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
131I-radretumab	DMT17XU	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[2]
JSM 6427	DM4QIOH	Macular degeneration	9B78.3	Phase 1	[3]
OS2966	DMS8NM5	Glioblastoma of brain	2A00.00	Phase 1	[4]
SB-265123	DM8UKH7	Discovery agent	N.A.	Investigative	[5]
MK-0668	DMVBFJP	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting ITGB3 messenger RNA (ITGB3 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XEMILOFIBAN	DMBRYT8	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 3	[7]
DMP-802	DMDK6HP	N. A.	N. A.	Discontinued in Phase 1	[8]
SC-47643	DMIE039	N. A.	N. A.	Terminated	[9]
SB-223245	DM3JQCF	N. A.	N. A.	Terminated	[10]
L-709780	DMB3ZTI	N. A.	N. A.	Terminated	[11]
Ro-43-8857	DM4VY8S	N. A.	N. A.	Terminated	[8]
SKF-107260	DMM8F0V	N. A.	N. A.	Terminated	[12]
L-738167	DMO69X8	N. A.	N. A.	Terminated	[8]
DMP-757	DMGNUXC	N. A.	N. A.	Terminated	[13]
Ro-43-5054	DMPNHF0	N. A.	N. A.	Terminated	[8]

Drug(s) Targeting Integrin alpha-5 (ITGA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JSM 6427	DM4QIOH	Macular degeneration	9B78.3	Phase 1	[3]
GW-559090	DM1FIN9	Allergic rhinitis	CA08.0	Discontinued in Phase 2	[14]
TR-14531	DMH5SA6	Asthma	CA23	Discontinued in Phase 1	[15]
ZD-7349	DM1EB6H	Multiple sclerosis	8A40	Discontinued in Phase 1	[16]
DW-908e	DMXJ54Z	Allergy	4A80-4A85	Discontinued in Phase 1	[17]

Drug(s) Targeting Integrin alpha-V (ITGAV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abituzumab	DMTCXSG	Colorectal cancer	2B91.Z	Phase 2	[18]
IMGN-388	DMSYB83	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
SB-223245	DM3JQCF	N. A.	N. A.	Terminated	[10]
SB-265123	DM8UKH7	Discovery agent	N.A.	Investigative	[20]
C(RGDfF)	DMMBESU	Discovery agent	N.A.	Investigative	[21]
Ac-Asp-Arg-Leu-Asp-Ser-OH	DMYHADT	Discovery agent	N.A.	Investigative	[22]
C[-Arg-Gly-Asp-Acpca21-]	DMXCUDV	Discovery agent	N.A.	Investigative	[23]
C-[-Arg-Gly-Asp-Acpca32-]	DMVM7B2	Discovery agent	N.A.	Investigative	[23]
Cyclo-[-Arg-Gly-Asp-Amp22-]	DMBELJK	Discovery agent	N.A.	Investigative	[24]
Cyclo-[-Arg-Gly-Asp-Amp21-]	DMVXPUB	Discovery agent	N.A.	Investigative	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-5 (ITGA5)	TTHIZP9	ITA5_HUMAN	Inhibitor	[1]
Integrin alpha-V (ITGAV)	TTT1R2L	ITAV_HUMAN	Inhibitor	[1]
Integrin beta-1 (ITGB1)	TTBVIQC	ITB1_HUMAN	Inhibitor	[1]
ITGB3 messenger RNA (ITGB3 mRNA)	TTJA1ZO	ITB3_HUMAN	Inhibitor	[1]

References

• [1] Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
• [2] Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43.
• [3] An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85.
• [4] Convection-Enhanced Delivery of a First-in-Class Anti-beta1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging. Pharmaceutics. 2020 Dec 30;13(1):40.
• [5] Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12.
• [6] Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalan... Bioorg Med Chem Lett. 2009 Oct 1;19(19):5803-6.
• [7] Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. J Med Chem. 1999 Dec 16;42(25):5254-65.
• [8] Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
• [9] Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem. 1995 Jan 6;38(1):34-41.
• [10] Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a resten... Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6.
• [11] Non-peptide fibrinogen receptor antagonists. 3. design and discovery of a centrally constrained inhibitorc, Bioorg. Med. Chem. Lett. 4(15):1835-1840 (1994).
• [12] Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993).
• [13] Synthesis and antiplatelet activity of DMP 757 analogs, Bioorg. Med. Chem. Lett. 5(18):2097-2100 (1995).
• [14] Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukoc Biol. 2008 January; 83(1): 1-12.
• [15] US patent application no. US2010278784 (A1), Methods and compositions for treating skin conditions.
• [16] Eosinophil adhesion to cholinergic nerves via ICAM-1 and VCAM-1 and associated eosinophil degranulation. Am J Physiol Lung Cell Mol Physiol. 2002 Jun;282(6):L1279-88.
• [17] WO patent application no. 2008,1439,28, Methods and compositions for treating skin conditions.
• [18] Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-40.
• [19] Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010 Oct 1;70(19):7591-9.
• [20] 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41.
• [21] Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
• [22] Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one sc... Bioorg Med Chem. 2007 Dec 1;15(23):7380-90.
• [23] Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
• [24] Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.